Database Solutions - Press View
Press View - Over 20,000 press releases analysis on global drug companies key events
Drugs - Over 30,000 pipeline and commercial innovator drugs detaills
Clinical Trials - Over 250,000 clinical trials with locations and investigators
Companies - 9,000 plus companies key data analysis
R&D Trend View
Research Trends - Identify new research findings with similar market players analysis
Market Trends - Analysis based on drug pricing and companie strategies
Clinical Trials Trends - Patients recruitment analyisis and predictions
Companies Trends - Market players analysis with licensing agreements and acquisitions & mergers trends
News Letters, Email Alerts & Saved Searches
Daily/Weekly news letter - Predefined filtered data by development and company key events
Daily/Weekly email alerts - Customized data alerts through user specific alerts settings
Saved searches - Source URL's with 'Saved searches' gets up-to-date data
Latest software technologies create compatable platforms for global users
Dynamic web crawlers on key data sources ensures timely updates
In-house methodologies with predictive analysis helps you to get insightful data
Industry driven classifications with thorough regulatory and market understanding
Provides 360 degree coverage that makes you stay ahead in competitive environment
Bridge R&D scientific approach continuously identify upcoming trends in drug research developent
Live query demo calls on database functionalities helps users with better data insights
Instant email access to expert analysts and ready to chat options enable users with quick replies
On job scientific assistance clarifies technical disparities which inturn enhances databases standardization
AUSTIN, Texas, May 24, 2019/- XBiotech announced plans to launch its dermatology program for its true human antibody bermekimab with the launch of a randomized, placebo-controlled, double-blind, phase 2b study in patients with moderate to severe hidradenitis suppurativa (HS).Read more..
NEW YORK, May 23, 2019/-- Tyme Technologies, Inc., an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced the initiation of the HopES trial conducted in partnership with The Joseph Ahmed Foundation to better understand and help manage high-risk sarcomas which are ultra-rare cancers with high unmet medical need.Read more..
SAN DIEGO, May 21, 2019/-- Heron Therapeutics, Inc, a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the results from the pivotal Phase 3 EPOCH 1 bunionectomy study of the investigational agent HTX-011Read more..
TOKYO and LONDON, May 22, 2019/-- Sosei Group Corporation,notes that its partner Novartis presented key Phase II data for QVM149, a potential new inhaled combination therapy for asthma, at the 2019 annual international congress of the American Thoracic Society (ATS) in Dallas, USA (17–22 May 2019).Read more..